PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Maria Coakley

Institute of Cancer Research

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 13, 2026 · JOURNAL ARTICLE

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer

JAMA Oncology

A well-designed prospective prognostic study in a defined population showing tissue-free ctDNA strongly predicts recurrence and performs comparably to tumor-informed assays, but uses surrogate endpoints (lead time, detection concordance) rather than direct clinical outcomes, and requires confirmation in a prospective trial.

PromisingNiamh Cunningham Cancer Genomics and Diagnostics Prithika Sritharan

Reported

Sample size159

Plasma samples analysed1026

ctDNA detection rate (tissue-free)54/159 (34.0%)

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support